• Recruiting

NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib RRMM

Updated: Jun 13

Multiple Myeloma Research Consortium


NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

ruxolitinib-myeloma

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma


The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase II is to evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects who receive the combination treatment carfilzomib, dexamethasone, and ruxolitinib.


Sponsor

Wake Forest University Health Sciences


Collaborators

Incyte Corporation

Multiple Myeloma Research Consortium

Amgen

 

ClinicalTrials.gov Identifier: NCT03773107


Official Title: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Phase I/II Study of Carfilzomib, Ruxolitinib, and Low Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma


First Posted: December 12, 2018


Click here to see details on ClinicalTrials.gov

 

Drug: Carfilzomib

Drug: Ruxolitinib

Drug: Dexamethasone

 

Locations:

United States, Michigan

Karmanos Cancer Institute, Detroit, Michigan


United States, North Carolina

Levine Cancer Institute

Charlotte, North Carolina


Posts Archive